Naveen Pemmaraju shared a post on LinkedIn:

“This past week, surrounded by dear friends & trusted colleagues, as part of the MDACC Cancer Network Leadership team, I had the honor of celebrating the official launch of RUSH MD Anderson Cancer Center together with our colleagues at RUSH in Chicago! Stronger Together RUSH University Medical Center, MD Anderson Cancer Center. | Thank you President Peter Pisters , Chief Cancer Network Officer Dr Jeffrey E. Lee, M.D. Senior VP Chris McKee , Division Head of Cancer Medicine , Dr Christopher R. Flowers, Dana Hoyland Lee, Brenda Pesek, Shauna Choi, Marvetta Walker, Toby Clemmen May, Michael Overman, Joel Cox, Jennifer Litton, Grace Abdulmassih, Henry Kuerer, Alejandro Contreras,
Lindsay Myers, Monica J. de la Cerda
and Network Executive Directors Dr C Roland and Dr Elizabeth Rebello and Dr Naveen Pemmaraju.”

Source: Naveen Pemmaraju/LinkedIn

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML. He has been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020, which is one of the world’s most active BPDCN research programs. Dr. Pemmaraju is the recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. He is a well-known social media influencer and advocate.